We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tumor-Suppressor Genes Found for Lung Cancer

By Biotechdaily staff writers
Posted on 24 May 2002
A 10-year research project has culminated in the discovery of three lung-cancer tumor- suppressor genes on chromosome 3 that have dramatically reduced human lung cancer growth in mice. More...
Gene therapy trials with humans are scheduled to begin within a year.

The findings, by researchers from the University of Texas (UT) M.D. Anderson Cancer Center (Houston, USA) and the UT Southwestern Medical Center at Dallas (USA), was published in the May 1, 2002, issue of Cancer Research.

Working from a set of about 20 genes previously identified as possible tumor- suppressors, researchers focused on a small region of chromosome 3, where they identified eight possible tumor-suppressor genes. Using new adenovirus technology,
the researchers tested their effectiveness and found three genes that not only inhibited tumor growth and metastasis but induced cell death in human lung cancer cells.

"This is the earliest genetic change yet identified in lung cancer, a change that can take place in normal-looking lung tissue,” said Dr. Jack Roth, chairman of the department of thoracic and cardiovascular surgery at M.D. Anderson and co-principal investigator.

The researchers used the 3p genes to treat human lung cancers growing in mice, where the treatment caused a dramatic regression of tumors. They introduced the cancer systemically in the mice and then introduced the gene therapy in the same way. Systemic therapy also demonstrated effectiveness for reducing metastatic tumors. The discovery of the tumor-suppressor genes may lead to earlier detection, diagnosis, prevention, and treatment of lung cancer, say the researchers.




Related Links:
M.D. Anderson

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.